Hong Kong Stocks Open Lower; Simcere Pharmaceutical Surges on Roche Deal

Hong Kong equities opened lower on Tuesday, following a negative lead from U.S. markets and a decline in precious metals prices. The benchmark Hang Seng Index slipped 0.19% to 25,280.82 at the start of trading, according to data from Zhitong Finance App cited by Investing.com.

Market Snapshot

Other key gauges also started the day in negative territory, with investor sentiment dampened by overnight weakness in global markets. Pre-market turnover for the broader market was approximately HK$8.238 billion.

• The Hang Seng Tech Index fell by 0.41% to 4,532.22.
• The Hang Seng China Enterprises Index declined by 0.18% to 8,447.25.

Sector Divergence: Pharma Gains as Gold Tumbles

Ad

The pharmaceutical sector was a notable bright spot, outperforming the wider market. Simcere Pharmaceutical (02096) surged nearly 5% after announcing a global development and commercialization licensing partnership with Roche for its trispecific antibody, SIM0660. The potential value of the transaction exceeds $1.53 billion. Other gainers included Yuyun Health (01952), also up nearly 5%, and data center operator SUNeVision Holdings (01686), which rose almost 7%.

In contrast, gold mining stocks fell broadly as the price of the precious metal declined. Shandong Gold (01787) dropped nearly 5%, while Lingbao Gold (03330) and Zijin Mining (02259) were both down over 4%. The property and construction sector also faced pressure, with Onewo (02602) falling nearly 7%.

Global Headwinds Weigh on Sentiment

The soft open in Hong Kong was largely attributed to a sell-off on Wall Street. Overnight, all three major U.S. indices closed lower, with the Dow Jones Industrial Average falling 0.79%, the S&P 500 losing 0.71%, and the Nasdaq Composite dropping 1.03%. Spot gold also registered a significant decline of 2.48%, adding to the risk-off mood.